Further studies, in larger series of BM samples from patients with distinct disease conditions, are necessary to fully characterize these cells and to determine whether the expression of CD13, CD105 and CD45 is stable enough to be used as a backbone combination for the identification and characterization of BM MSCs in patients with distinct hematological malignancies and other hematological and nonhematological disorders. The gene discussed is PTPRC; the disease is hematologic disorder.